Dermatofibroma secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) No edit summary |
Homa Najafi (talk | contribs) No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}, {{AE}}{{Homa}} | {{CMG}}, {{AE}}{{Homa}} | ||
==Overview== | |||
There are no established measures for the secondary prevention of [disease name]. | |||
OR | |||
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3]. | |||
==Secondary Prevention== | |||
There are no established measures for the secondary prevention of [disease name]. | |||
OR | |||
Effective measures for the secondary prevention of [disease name] include: | |||
*[Strategy 1] | |||
*[Strategy 2] | |||
*[Strategy 3] | |||
==References== | ==References== | ||
{{Reflist|2}} | |||
{{ | {{WH}} | ||
{{WS}} | |||
[[Category:Needs content]] | [[Category:Needs content]] |
Revision as of 21:31, 10 June 2019
Dermatofibroma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Dermatofibroma secondary prevention On the Web |
American Roentgen Ray Society Images of Dermatofibroma secondary prevention |
Risk calculators and risk factors for Dermatofibroma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include:
- [Strategy 1]
- [Strategy 2]
- [Strategy 3]